To induce tolerance to a variety of epitopes, we have designed a gene therapy approach in which peptides or antigens are expressed in frame on a soluble IgG fusion protein scaffold and delivered via retroviral gene therapy in B cells in vivo. Initially, tolerance to the l repressor cI sequence p1±102 or its immunodominant epitopes (e.g. p12±26 or p73±88) was elicited in both T cells and B cells when lipopolysaccharide (LPS) blasts are transduced and injected into naive or even primed recipients. While a role of secreted Ig fusion protein in this process is not clear, we have previously demonstrated the importance of antigen presentation on MHC class II of B cell antigenpresenting cells (APC) for tolerance induction. To further examine the role of the Ig and especially of the Fc portion of the IgG in tolerogenesis, we transduced LPS blasts from FcRgII ±/± , FcgRI ±/± , FcgRIII ±/± , FcR ±/± or naive mice with retroviral vectors expressing IgG1±102, DIgG1±102 (mutated construct on position 297 of the Fc portion) or IgG12±26. When these transduced LPS blasts from FcR knockout mice were injected into normal (or knockout) syngeneic recipient mice, they induced tolerance both to the immunodominant epitopes and the full-length protein in that the antibody responses to the immunodominant epitopes were reduced. In this paper, we show that this tolerance resides at both the T and B cell level. Moreover, mutation of residue 297, which affects IgG functions including FcR binding, did not alter the tolerogenicity of the construct. These results suggest that the Fc portion of the IgG molecules is not required for humoral nor for cellular tolerance induction using the IgG±antigen tolerogens.
Introduction
The use of IgG carriers to induce immune tolerance to speci®c peptides or antigens has been studied for several years (1±4). We have developed a gene-therapy-based approach in which murine IgG1 heavy chains are subcloned in-frame with antigens (peptides or full-length proteins) in retroviral vectors (5) . B cells transduced with these retroviral vectors ef®ciently induce B cell and T cell tolerance in vivo (5±8). We originally expected that the long half-life of IgG carriers, their ability to disseminate between intra-and extravascular spaces, and their interaction with a variety of antigen-presenting cells (APC) by FcR, may contribute to their ef®cacy in tolerance induction. Interestingly, deletion of the IgG heavy chain reduced the ef®cacy and affected the persistence of the tolerant state (6) . However, the amount of Ig fusion protein in the circulation of recipients of IgG fusion protein-transduced B cells never correlated with the degree of unresponsiveness (5) . Thus, the role of the Fc and FcR in tolerance induction remained unclear.
To further understand the mechanisms of tolerance induction by Ig tolerogens, we recently tested whether MHC class II knockout or B cell knockout (mMT) donors could serve as a source of tolerogenic APC in our gene therapy model. Our data was consistent with the clear involvement of B cells and the necessity of presentation on MHC class II molecules (8) . Moreover, no evidence for a role of regulatory cytokines such as IL-10 has been observed (8) . This work demonstrated the importance of presentation in our model of tolerance induction, but did not shed light on the possibility that the IgG± antigen (Ag) molecules still can be assembled, secreted and taken up by a neighboring APC and re-presented on MHC class II molecules of the transfected B cell. This process could involve FcR present on most APC. In this paper we investigate the role that FcR play in tolerance induction by IgG±Ag tolerogens. Our results show that neither T cell nor B cell tolerance is in¯uenced by FcR family members on APC.
Methods

Mice
CB6 F1/J (BALB/c Q C57Bl/6) and C57Bl/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME), while Fcer1g/Fcgr2b (FcR double-knockout on a C57Bl/6 Q 129 F 1 background), B6 Q 129 F 1 (wild-type for FcR doubleknockout on a C56Bl/6 Q 129/J background) and Fcgr2b (FcgRII knockout on a BALB/c background) mice were purchased from Taconic Laboratory (Germantown, NY). BALB/c mice were purchased from NCI (Frederick, MD). Fcer1g (FcgRI, FcgRIII and FceRI knockout, on C57Bl/6 background) are a kind gift from Dr Dragana Jankovic Â (NIAID, NIH, Bethesda, MD). All animals were initially used at 6±8 weeks of age and housed in pathogen-free microisolator cages in our animal facility.
Peptides and antigens
The major antigenic peptides of p1±102 in H-2 d and H-2 b mice, residues 12±26 (LEDARRLKAIYEKKK) and residues 73±88 (VEEFSPSIAREIYEMY) conjugated or not to BSA respectively (6), were synthesized in the New England Peptide (Fitchburg, MA) and were puri®ed to >95% homogeneity by HPLC. In addition, 12±26±BSA was used as an immunogen in B cell tolerance experiments since the BSA carrier can provide`help' for 12±26 B cells [(2,9) and see below].
Retroviral constructs and virus-producer cell lines
The p12±26±IgG construct contains only the major I-A drestricted 12±26 peptide in frame in the IgG1 heavy chain, as described previously (5±8). In addition, constructs containing ovalbumin (OVA), p1±102 (full-length cI lrepressor) inframe with the IgG1 heavy chain were also engineered for experimental use. A further construct Dp1±102 (mutated at position 297 Asn ® Ala of the murine IgG1 C region, using the QuickChange Site-Directed Mutagenesis kit; Stratagene, La Jolla, CA) was created for an IgG with no Fc-binding capability (10) . However, the failure of the Dp1±102±IgG to bind to FcR could not be validated for our fusion proteins because the transduced cells did not produce suf®cient quantities for analysis (M. Litzinger and D. Scott, data not shown). As the original murine IgG1 heavy chain binds with high af®nity to the NIP hapten when assembled with l light chain, the recombinant p12±26±IgG and p1±102±IgG fusion protein, can be detected with a NIP-gelatin binding ELISA, although this is an underestimate of secreted IgG fusion protein (5) .
Virus-producer cell lines were prepared by lipofection of second-generation GP-E86 packaging cell lines with p12±26± IgG±MBAE, p1±102±IgG±MBAE, Dp1±102±IgG±MBAE or OVA±IgG±MBAE retroviral constructs respectively, and were found to be helper virus-free and to contain~10 5 ±10 6 neomycin-resistant NIH 3T3 c.f.u./ml, using methods as described previously (5, 6, 8) .
Retroviral-mediated gene transfer to lipopolysaccharide (LPS)-stimulated B cell blasts
Retroviral-mediated gene transfer into bacterial LPS (Escherichia coli 055:B5; Sigma)-stimulated splenic B cells has been described elsewhere (4, 5, 7) . Brie¯y, primary culture of splenocytes was stimulated for 24 h with 30 mg/ml of LPS. Cells were then cultured (3 Q 10 6 cell/ml) for an additional 24 h with supernatant enriched with retroviruses of the indicated peptide±IgG in the presence of 3 mg/ml polybrene and LPS. Naive wild-type mice (or knockout mice, see below) then received 2 Q 10 7 B cell blasts i.p.
Immunologic protocols
Five days after adoptive transfer of transduced B cells, mice were immunized s.c. in one footpad and at the base of the tail with 25 mg of recombinant p1±102 protein or 25 mg of p12±26 plus 25 mg OVA (as a speci®city control) emulsi®ed 1:1 in complete Freund's adjuvant (CFA). For testing B cell tolerance, mice were immunized with 25 mg of 12±26 coupled to BSA, as a helper carrier, in CFA. Two weeks later, mice were bled for the measurement of serum primary antibody responses. The mice were then either euthanized and cellular immune responses in lymph nodes and spleen determined, or boosted i.p. with 25 mg of p1±102 protein, p12±26 or 12±26± BSA and 25 mg of OVA in PBS. The secondary antibody responses were measured from sera collected 1 week after the boosting. Serum p73±88-speci®c, p12±26-speci®c or OVA-speci®c IgG responses were determined by ELISA. Plates were coated with 1 mg/ml of synthetic peptide p12±26 or p73±88 conjugated to BSA (with synthetic peptide only when 12±26±BSA was used), or 1 mg/ml of OVA or p1±102. Plates were subsequently probed with alkaline phosphatase-conjugated goat anti-mouse IgG as a secondary reagent (Southern Biotechnology Associates, Birmingham, AL). Total anti-12±26 IgG concentrations were calculated using a standard curve with known concentrations of target antigen and mAb B3.11, speci®c for the p12±26 epitope of p1±102, as standard. Antip73±88 of p1±102 and anti-OVA (speci®city control) were also determined by ELISA. Lymph node T cell responses were measured in vitro using [ 3 H]thymidine incorporation, as described previously (8) .
Results
FcgRII deletion has no effect on tolerance induction by IgG± Ag molecules
We originally expected that the excellent tolerogenicity of IgG carriers was due in part to their persistence and to their interaction with a variety of APC by Fc receptors. However, the tolerogenicity of gene-transferred Ig fusion proteins did not correlate with the amount of circulating IgG±Ag (5) . Moreover, use of MHC class II knockouts as B cell donors suggested an important role for presentation by the transduced B cells as paramount in tolerance induction (8) . This result did not eliminate the possibility that these B cell APC secrete and ef®ciently present Ig-Ag after FcR uptake. To test the hypothesis that IgG tolerogens may be secreted, taken up and presented on MHC class II molecules by B cell APC, we used knockouts for the three major classes of FcR. Because FcgRII is present mainly on lymphoid and myeloid lineages (10, 11) and is of low af®nity to IgG, we transduced activated splenocytes from FcgRII ±/± or wild-type with either p12±26± IgG or OVA±IgG and injected them into naive (+/+) recipients in our standard gene therapy protocol (5, 6, 8) . After challenge and boost with 12±26 and OVA, the levels of anti-12±26 antibodies in the recipients of transduced p12±26±IgG FcgRII ±/± and the p12±26±IgG B cells were signi®cantly reduced (i.e. tolerant) compared to control regardless of the source of the B cell APC (Fig. 1A, top) . As previously reported (5, 8) , tolerance was speci®c in that the antibody response to OVA was normal in 12±26±IgG B cell-treated mice, but reduced in recipients of OVA±IgG-treated B cells (Fig. 1A,  bottom) . These results show that humoral tolerance was induced in recipients of p12±26±IgG FcgRII ±/± and that its induction is not in¯uenced by the removal of FcgRII. Similar results were obtained with FcR ±/± knockout recipients, thus eliminating the role of host cells in tolerance ( Knowing that FcgRI-binding af®nity to IgG is highest among the other FcR (10,11), we used splenocytes from FcgR ±/± lacking the expression of FcgRI, FcgRIII and FceRI. LPSactivated spleen cells from FcgR ±/± or wild-type donors were transduced with p1±102±IgG or OVA±IgG were injected into naive mice. The data in Fig. 2 show that FcgR on the tolerogenic APC do not in¯uence the ability to induce B cell tolerance, as measured by the humoral response to p12±26. This suggests that secretion of the IgG±Ag and its uptake by FcgRI is not involved in this pathway of B cell tolerance induction.
Total FcR deletion does not affect IgG±Ag induction of B or T cell tolerance
In order to further test the role of FcR in tolerance induction by IgG±Ag tolerogens, we used splenocytes from double-knockout mice lacking all FcR and transferred them into syngeneic naive mice after retroviral transduction with p1±102±IgG and OVA±IgG. We used p1±102±IgG in order to follow the response to epitopes recognized by the background strains (6); thus, tolerance, presumably in helper T and B cells, was measured as antibody secondary responses to p73±88 or fulllength p1±102. We found a signi®cant decrease in the levels of total IgG anti-73±88 and anti-1±102 in groups that received the tolerogen-transduced splenocyte blasts from wild-type or total FcR ±/± as compared to control (Fig. 3A) . In addition, T cell responsiveness, measured by lymph node T cell proliferation from mice receiving transduced knockout or wild-type blasts, showed that T cell tolerance was not affected in this experiment against p73±88 (Fig. 3B) . These data also suggest that the involvement of FcR in T or B cell tolerance induced by IgG± Ag tolerogens is minimal. Again, tolerance was speci®c as measured by responsiveness to OVA in p1±102±IgG-treated B cell recipients (data not shown).
Mutation of the Fc portion of IgG1 at position 297 has no effect on tolerance induction
In an attempt to further understand the role of the Fc portion of murine IgG in the mechanisms of tolerance induction using IgG±Ag tolerogens, we mutated the C region of the heavy chain at position 297 of the p1±102±IgG construct. This particular amino acid is known to be a conserved glycosylation site that was found to be critical for binding and activation of IgG molecules to all three FcgR and in complement-mediated lysis (10±15). Thus, normal mice can be used as donors and recipients to eliminate any in¯uence of knockout background genes. Mice were injected with transduced lymphocytes with mock cells, p1±102±IgG or the mutated construct Dp1±102± IgG. Tolerance (B cell) was assessed by measuring the levels of circulating anti-1±102 or anti-12±26 antibodies and cellular tolerance was assessed using standard lymph node T cell proliferation to immunodominant peptides. Tolerance to p1± 102 or its immunodominant peptide 12±26 was no different in groups receiving p1±102±IgG or Dp1±102±IgG as compared to mice receiving mock injection ( Fig. 4A and B) . Although presence of the heavy chain in¯uences the maintenance of tolerance with IgG chimeras (6), these results suggest that the Fc fragment of the IgG is not involved because the mutated construct did not alter the tolerance induction to 1±102 or its immunodominant peptide 12±26. These data also suggest that secretion and uptake is probably not the preferential way by which IgG±Ag fusion protein induces tolerance.
Humoral tolerance in gene-transferred recipients is due in part to speci®c B cell tolerance
The fact that humoral tolerance to p1±102, p12±26 and p73±88 was reduced signi®cantly in the above experiments (Figs 1±4) suggested that both B and T cell tolerance was being induced, as previously reported (5). However, we need to formally test that the reduced IgG titers against those peptides was due to B cell [in addition to T h (9) ] tolerance induction by the transferred IgG±Ag fusion protein construct. Therefore, recipients of B cell blasts transduced with p12±26±IgG were challenged with p12±26 coupled to BSA in CFA to provide BSA-speci®c T cell help (3, 6, 16) . They were boosted with 12± 26±BSA in saline 2 weeks later. IgG titers of anti-12±26 were signi®cantly lower in the 12±26±BSA-challenged group of treated mice. However, the titers were signi®cantly higher than the tolerant control group challenged with 12±26 alone (195 mg/ml in the p12±26±IgG group challenged with 12±26±BSA versus 56 mg/ml in the p12±26±IgG group challenged with 12± 26 alone). This may be due to the presence of both B and partial T cell tolerance in mice challenged with 12±26 (which has both a T cell and a B cell epitope), whereas only B cell tolerance is revealed with 12±26±BSA, in which BSA-speci®c T cells can provide help to partially overcome tolerance.
Discussion
FcR are known to balance the immune response, and the lack of any of them can lead to autoimmunity and in¯ammation mediated by T cells (10±15). However, the role that FcR play in tolerance is poorly understood. Based on the excellent tolerogenicity of IgG carriers (1±5,9), it was assumed that the Fc portion of the IgG might be important in tolerance. In fact, IgG is more tolerogenic than F(ab) 2 fragments (16) and clearly leads to greater persistence in vivo. Moreover, deletion of the IgG carrier reduces both the ef®cacy and persistence of gene-therapy-induced tolerance (6). As noted above, however, the tolerogenicity of gene-transferred Ig fusion proteins does not correlate with the amount of circulating IgG±Ag (5). Fig. 2 . FcgR are not involved in humoral tolerance induction. C57Bl/6 mice were injected with 2 Q 10 7 p1±102±IgG or OVA±IgG genetransferred B cell blasts from naive C57Bl/6 or FcgR ±/± mice, which lack FcgRI, FcgRIII and FceRI. Five days later, mice were immunized with 25 mg of p12±26 and 25 mg of OVA emulsi®ed 1:1 in CFA. Two weeks later, mice were boosted with the same antigens in PBS. A week after boost, all mice were bled for determination of anti-p73±88 and anti-OVA (data not shown) titers by ELISA. Antibody IgG total serum levels against p73±88 in recipient mice of p1±102±IgG-transduced B cell blasts are represented by open columns, while those of controls receiving OVA±IgG transduced B cell blasts are represented by solid columns (total IgG P < 0.001). Data are presented as means T SE. One of two representative experiments is shown, with ®ve mice per group. OVA±IgG represents the control group retrovirally transduced with an unrelated construct, whereas p1±102±IgG represents experimental group and knockout represents recipients of FcgR knockout B cell blast. As in Fig. 1 , tolerance was speci®c (data not shown). That result, coupled with the failure of B cells from MHC class II knockouts to be tolerogenic APC (8) , suggested that presentation by transfected B cells was most critical in tolerance induction. However, this did not rule out a role for uptake and processing of the expressed chimeric protein by these cells. This necessitated further study of the role of FcR in this tolerance model. The results presented herein, however, suggest that FcR are not important in tolerance induced by IgG±Ag in this model.
In this study, we directly tested the hypothesis that the IgG± Ag tolerogen enters the presenting B cells via the FcR and is then presented on B cell APC's MHC class II for tolerance induction. Using our gene therapy model for tolerance, our results showed that humoral tolerance is not affected by the deletion of FcR nor by the mutation of the Fc portion of the murine Ig. This suggests that secretion of the IgG and its uptake by FcR is not a major part of the mechanism by which tolerance is induced using the IgG±Ag chimeras. In addition, it has been reported that tolerance induction in FcR knockout mice can be induced at both cellular and humoral levels (17) . Our results support those ®ndings despite differences in the systems, especially the dose of antigen. Despite the fact that FcR may play a role in enhancing antigen presentation (18, 19) , the lack of those molecules did not attenuate cellular tolerance in our system. In addition, in vivo anti-FcR (2.4G2) treatment of transgenic mice expressing and secreting as much as 10 mg/ ml of 12±26±IgG by B cells (20) showed no effect on tolerance induction at the cellular and humoral levels, and in terms of cytokine levels (El-Amine and Scott, unpublished data). Thus, the secretion and uptake hypothesis also was not supported by the results from the mutation in the Fc portion of the Ig that showed both humoral and cellular tolerance (Fig. 4) in all groups. These data, in addition to an MHC class II knockout result from our previous studies (8) showing reversal of tolerance in the absence of B cell presentation, clearly shows that docking of the IgG±Ag fusion protein on the FcR is not necessary for tolerance induction. Nonetheless, while our data support the hypothesis of presentation rather than secretion and uptake as paramount in this model of tolerance, additional work with constructs lacking a signal sequence to prevent secretion is needed to prove that endogenous presentation is suf®cient for tolerance.
Finally, tolerance induction using IgG±Ag is a powerful approach for tolerance induction that can be used in human clinical trials and is currently used in clinical animal models (7, 21, 22) for treatment of autoimmune diseases. The mechanisms behind this tolerance induction are important to elucidate better manipulation of the system in the future. 
